NCT00253734View on ClinicalTrials.gov

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

PHASE2CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2006

Study Completion Date

November 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone® (IM)

15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.

BIOLOGICAL

Fluzone®

9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).

Trial Locations (1)

63110

Saint Louis University, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00253734 - Immunogenicity and Safety of Different Doses of Fluzone® Influenza | Biotech Hunter | Biotech Hunter